Saturday, July 11, 2026

Drug profile · INN

remicade

remicade is a tnf-alpha inhibitor.

NMPA: clinical trials
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — remicade
Class
Route
Patents
0
Programs
2
Data quality
0.70

Quick answer

remicade is a tnf-alpha inhibitor.

Key facts

INN remicade
Mechanism TNF-alpha inhibitor
Target Tumor necrosis factor

Mechanism of action

TNF-alpha inhibitor

Primary target: Tumor necrosis factor

Approval history

Authority Status Date
NMPA clinical trials

Pipeline programs

  1. infliximab (Remicade) Phase 2 · Universal Integrated · COPD
  2. remicade (anti tumor necrosis factor inhibitor) Phase 2 · Hospital Authority · Takayasu's Arteritis

Related & competitor drugs

  1. adalimumab-aqvh TNF-alpha inhibitor
  2. denosumab Musculo-skeletal system (M05)
  3. adalimumab-aacf TNF-alpha inhibitor
  4. adalimumab-aaty TNF-alpha inhibitor
  5. adalimumab-adaz TNF-alpha inhibitor
  6. adalimumab-adbm TNF-alpha inhibitor

Frequently asked questions

What is remicade?

remicade is a tnf-alpha inhibitor.